Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: CRISPR Therapeutics Q2 Adj. EPS $(1.29) Beats $(1.47) Estimate, Sales $892.000K Miss $6.255M Estimate

Author: Benzinga Newsdesk | August 04, 2025 05:05pm
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.29) per share which beat the analyst consensus estimate of $(1.47) by 11.95 percent. This is a 13.42 percent increase over losses of $(1.49) per share from the same period last year. The company reported quarterly sales of $892.000 thousand which missed the analyst consensus estimate of $6.255 million by 85.74 percent. This is a 72.53 percent increase over sales of $517.000 thousand the same period last year.

Posted In: CRSP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist